<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02410954</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00059590</org_study_id>
    <nct_id>NCT02410954</nct_id>
  </id_info>
  <brief_title>Transcranial Direct Current Stimulation (tDCS) as a Treatment for Acute Fear</brief_title>
  <acronym>tDCS</acronym>
  <official_title>Transcranial Direct Current Stimulation (tDCS) as a Treatment for Acute Fear</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Locus coeruleus (LC) norepinephrine (NE) neuron activity has been convincingly linked to&#xD;
      regulation of acute fear. This study will address whether LC NE activity examined through&#xD;
      pupil measures will reflect carbon dioxide (CO2) induced fear-responses in humans and if&#xD;
      transcranial direct current stimulation (tDCS) can mitigate these effects. A 2 year R21 phase&#xD;
      establishing feasibility, tolerability, safety, and proof-of-concept (POC) in terms of&#xD;
      capacity to engage LC NE neurons with tDCS, followed by a 3 year R33 parallel-group,&#xD;
      double-blind, randomized, controlled trial will determine the degree to which engaging LC NE&#xD;
      neurons with tDCS improves clinical symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The National Institutes of Mental Health (NIMH) has recently identified that a major&#xD;
      limitation to the understanding of neuropsychiatric disorders and the development of&#xD;
      treatments for these conditions has been the inability to identify key dimensions of&#xD;
      observable behavior that are central to these disorders and linked to underlying neurobiology&#xD;
      by measurable biomarkers. This project is intended to address this problem by establishing&#xD;
      that pupillary measures of norepinephrine (NE) neuronal activity are biomarkers of fear&#xD;
      dimension of observable behavior, alterations of which are believed to be core features of&#xD;
      neuropsychiatric conditions such as anxiety disorders. The investigators will establish this&#xD;
      biomarker-clinical dimension link by comparing pupillary indices in humans to a carbon&#xD;
      dioxide (CO2) fear provocation test, as well as in these subjects undergoing transcranial&#xD;
      Direct Current Stimulation (tDCS) prior to and after CO2 administration.&#xD;
&#xD;
      Participants will be recruited in Dr. Krystal's laboratory at Duke University which has&#xD;
      proven infrastructure for clinical trials. The study team plans to enroll a total of 240&#xD;
      subjects healthy volunteers (age range: 21-65 years) in order to complete 100. This takes&#xD;
      into account the expected rate of failure to: have a pupillary response in the auditory&#xD;
      oddball task (AOT) (25%); have a sufficient fear response to CO2 challenge (50% - relevant&#xD;
      for last 10 R21 and all R33 subjects); and to meet other screening criteria.&#xD;
&#xD;
      R21 Phase: First 30 Subjects will undergo two sessions separated by 1 week in which a&#xD;
      promising electrode configuration (three promising configuration will each be tested in a&#xD;
      cohort of 10 subjects) will be used with tDCS stimulation at increasing electrical dosage&#xD;
      during which pupillometry will be carried out to determine the auditory oddball test (AOT)&#xD;
      response. A maximum of 5 total tDCS dosages and sham will be tested. Last 10 Subjects. These&#xD;
      subjects will take part in a double-blind, controlled, randomized, cross-over study over 3&#xD;
      sessions. At session 1 subjects will undergo electrical dose titration with the tDCS&#xD;
      electrode configuration resulting from the 3 rounds of optimization using the same procedure&#xD;
      as in the first 30 subjects to determine the lowest well-tolerated dose that suppresses the&#xD;
      AOT pupil response, except that a maximum of 5 tDCS dosages will be tested at this session.&#xD;
      At the third and fourth sessions (1 week apart) subjects will receive dose-optimized tDCS and&#xD;
      the control treatment with order randomized along with 7.5% CO2 (to evoke an LC response) for&#xD;
      20 minutes. The 7.5% CO2 will be delivered to us pre-mixed provided by Airgas. At these&#xD;
      sessions, the VAS-A and State Trait Anxiety-Inventory (STA-I) will be administered 5 minutes&#xD;
      prior to and just after the 20 minute session and Visual Analog Scale-Anxiety (VAS-A) will&#xD;
      also be obtained at 5, 10, 15, and 20 minute points of the CO2 inhalation. tDCS will be&#xD;
      administered during the last 5 minutes of the 20 minute CO2 inhalation period. Subjects will&#xD;
      be monitored for an hour post-session for safety and will undergo study physician assessment&#xD;
      to determine suitability to leave. Following the 2nd treatment session participation will end&#xD;
      except that subjects will be called the next day to assess for adverse effects and&#xD;
      appropriate care will be given if found. R33 Phase: 60 subjects will participate in a&#xD;
      double-blind, randomized, controlled, parallel-group trial. They will be randomized to either&#xD;
      active or control treatment and at the first post-screening visit they will undergo&#xD;
      electrical dose titration as described above for the treatment they are randomized to. For&#xD;
      all titrations, during the 5 minutes between tDCS treatments an unblinded member of the study&#xD;
      team not having contact with the subjects will compute their AOT pupil response and convey to&#xD;
      the tDCS treatment physician whether to continue or stop titration. Subjects randomized to&#xD;
      the control treatment will undergo a sham titration where the stop level will be randomly&#xD;
      selected from the distribution of titration outcomes occurring in the R21 phase. Subjects&#xD;
      will then return in 1 week and undergo optimal dose tDCS or control treatment for a single&#xD;
      treatment session as described in the prior paragraph. Primary outcome will be the VAS-A&#xD;
      &quot;fearful&quot; rating obtained at the end of tDCS/CO2 inhalation. AOT pupil response will be&#xD;
      obtained every 10 minutes after the end of the tDCS/CO2 inhalation period to map the duration&#xD;
      of persistent effects on LC. At the end of this session participation will end except that&#xD;
      subjects will be called the next day to assess for adverse effects and care given if&#xD;
      necessary. Preliminary data from the R21 phase will be used to provide justification for the&#xD;
      larger R33 study, and prior to commencing the R33 investigation phase that an addendum to the&#xD;
      Institutional Review Board (IRB) protocol with approval will be obtained.&#xD;
&#xD;
      Pupillometry Procedure. The team will employ fully mobile SensoMotoric Instruments (SMI)&#xD;
      Eye-tracking Glasses to carry out pupillometry. Pupil diameter will be recorded continuously&#xD;
      from the each eye at a sampling rate of 60 Hz via glasses on the subject's face. The&#xD;
      investigators will capture pupil size at baseline and in response to the AOT and&#xD;
      administration of 7.5% CO2. Data will be segmented into epochs from 0 to 12 s relative to the&#xD;
      acquisition onset of each stimuli or experimental condition. An average pupil diameter&#xD;
      measure will then be calculated for the corresponding volume by taking the mean across the&#xD;
      remaining non-artifactual samples in that epoch. For 7.5% CO2 response the pupil diameter&#xD;
      will be averaged over 1 minute periods while subjects are staring at a dark screen in a dark&#xD;
      room. This will be computed at baseline, and at 5, 10, 15, and 20 minutes after the start of&#xD;
      CO2 inhalation and 5 minutes and 30 minutes postinhalation.&#xD;
&#xD;
      Administration of 7.5% CO2. Inhalation of 7.5% CO2 for 20 min will be carried out. Subjects&#xD;
      will be instructed to avoid alcohol for 36 hours and caffeine for 12 hour prior to testing&#xD;
      and to eat a light lunch at least one hour prior to testing. A urine pregnancy test will be&#xD;
      administered to women of childbearing potential on both days of gas exposure with a negative&#xD;
      result needed in order to continue in study participation. Gas will be delivered via a&#xD;
      nasal-oral face mask connected via tubing to a 500 L reservoir bag filled with 7.5% CO2/21%&#xD;
      Oxygen (O2) 71.5% Nitrogen (N2). Subjects will receive air through the mask in the 10 min&#xD;
      prior to CO2 administration during which baseline measures will be obtained.&#xD;
&#xD;
      Transcranial Direct Current Stimulation (tDCS) will be administered with a multichannel&#xD;
      direct current stimulation device that can be programmed so that the operator doesn't know&#xD;
      the combination of electrodes being used for stimulation, and, thereby allow double-blinding.&#xD;
      The active tDCS electrode configuration to be used will be determined with the 3 round&#xD;
      iterative procedure described above; based on electric field modeling and personalized&#xD;
      electrical dose titration to find the lowest dose that is well-tolerated and engages the&#xD;
      target in terms of inhibiting the AOT pupillary response. Electrical dosage will be&#xD;
      personalized for each subject by titrating dosage (gradually increasing) until the dosage is&#xD;
      found that is both well-tolerated (no more than mild discomfort on a 5-point Likert scale)&#xD;
      and suppresses the AOT pupillary response. If the 5-point Likert tolerability rating is&#xD;
      greater than &quot;mild discomfort&quot; or if maximum amperage is reached without effect on AOT then&#xD;
      subject participation will terminate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">January 31, 2019</completion_date>
  <primary_completion_date type="Actual">January 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in VAS-A Rating</measure>
    <time_frame>Every 10 min (for approximately 20 minutes) at the end of tDCS/CO2 inhalation following one week post stimulation optimization.</time_frame>
    <description>Primary outcome will be the VAS-A &quot;fearful&quot; rating obtained at the end of tDCS/CO2 inhalation. AOT pupil response will be obtained every 10 minutes after the end of the tDCS/CO2 inhalation period to map the duration of persistent effects on LC.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Fear</condition>
  <arm_group>
    <arm_group_label>tDCS electrode configuration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three rounds of tDCS using NeuroConn Direct Current stimulator Multiple Channel -4, Rogue Resolutions treatment optimization where each round includes identifying a promising electrode configuration based on electric field modeling using a realistic head model and capitalizing on the experience with the prior round (for rounds 2 and 3) and testing that electrode placement by administering a series of electrical doses of tDCS with that tDCS electrode configuration (carrying out a dose titration) in a cohort of 10 healthy control subjects to see if we can find an electrical dose which is well-tolerated, safe, suppresses the AOT pupil response and is below recommended current density safety limits (the safety limit in terms of Amperage varies depending on the electrode configuration)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Using tDCS to reduce acute fear</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of 7.5% CO2 to see if this elicits symptoms of Acute Fear and activates LC and whether tDCS safely inhibits the LC response to 7.5% CO2 compared with sham in a pilot cross-over trial (N=10). A 3-year double-blind, randomized, controlled trial where clinical symptoms of Acute Fear, the primary outcome are elicited with 7.5% CO2 in healthy volunteers is the final study component.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeuroConn Direct Current stimulator Multiple Channel -4</intervention_name>
    <description>(tDCS) will be administered with a multichannel tDCS device that can be programmed so that the operator doesn't know the combination of electrodes being used for stimulation, and, thereby allow double-blinding. The active tDCS electrode configuration to be used will be determined with the 3 round iterative procedure described above; based on electric field modeling and personalized electrical dose titration to find the lowest dose that is well-tolerated and engages the target in terms of inhibiting the AOT pupillary response.</description>
    <arm_group_label>Using tDCS to reduce acute fear</arm_group_label>
    <arm_group_label>tDCS electrode configuration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Use of effective method of birth control for women of childbearing capacity&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
          -  Have a significant difference between the mean pupil diameter in response to odd and&#xD;
             common tones in the AOT during screening&#xD;
&#xD;
          -  The10 subjects in the R21 cross-over study and all of the R33 subjects must have a 26%&#xD;
             increase in VAS-A &quot;fearful&quot; response to 7.5% CO2 at the first CO2 challenge session&#xD;
&#xD;
          -  Able to follow study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or past Axis I Diagnostic and Statistical Manual (DSM-IV) disorder based on&#xD;
             the MINI&#xD;
&#xD;
          -  Current or past history of substance abuse or dependence (excluding nicotine) based on&#xD;
             history or positive urine toxicology&#xD;
&#xD;
          -  Current unstable medical condition&#xD;
&#xD;
          -  Any current neurological condition or medical condition that is known to affect&#xD;
             pupillary function, mood/anxiety, or neurologic function generally&#xD;
&#xD;
          -  Pregnancy based on Urine Pregnancy Test&#xD;
&#xD;
          -  Women who are breast-feeding&#xD;
&#xD;
          -  Use of medications known to affect Central Nervous System (CNS) function within 5&#xD;
             half-lives screening&#xD;
&#xD;
          -  Use of a pacemaker&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Krystal, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Insel TR. The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry. Am J Psychiatry. 2014 Apr;171(4):395-7. doi: 10.1176/appi.ajp.2014.14020138.</citation>
    <PMID>24687194</PMID>
  </reference>
  <reference>
    <citation>Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med. 2013 May 14;11:126. doi: 10.1186/1741-7015-11-126.</citation>
    <PMID>23672542</PMID>
  </reference>
  <reference>
    <citation>Redmond DE Jr, Huang YH. Current concepts. II. New evidence for a locus coeruleus-norepinephrine connection with anxiety. Life Sci. 1979 Dec 24;25(26):2149-62. Review.</citation>
    <PMID>120478</PMID>
  </reference>
  <reference>
    <citation>Nutt DJ. Altered central alpha 2-adrenoceptor sensitivity in panic disorder. Arch Gen Psychiatry. 1989 Feb;46(2):165-9.</citation>
    <PMID>2536539</PMID>
  </reference>
  <reference>
    <citation>LeDoux J. Emotional networks and motor control: a fearful view. Prog Brain Res. 1996;107:437-46. Review.</citation>
    <PMID>8782535</PMID>
  </reference>
  <reference>
    <citation>Gilzenrat MS, Nieuwenhuis S, Jepma M, Cohen JD. Pupil diameter tracks changes in control state predicted by the adaptive gain theory of locus coeruleus function. Cogn Affect Behav Neurosci. 2010 May;10(2):252-69. doi: 10.3758/CABN.10.2.252.</citation>
    <PMID>20498349</PMID>
  </reference>
  <reference>
    <citation>Nieuwenhuis S, Aston-Jones G, Cohen JD. Decision making, the P3, and the locus coeruleus-norepinephrine system. Psychol Bull. 2005 Jul;131(4):510-32. Review.</citation>
    <PMID>16060800</PMID>
  </reference>
  <reference>
    <citation>Aston-Jones G, Cohen JD. Adaptive gain and the role of the locus coeruleus-norepinephrine system in optimal performance. J Comp Neurol. 2005 Dec 5;493(1):99-110. Review.</citation>
    <PMID>16254995</PMID>
  </reference>
  <reference>
    <citation>Bailey JE, Argyropoulos SV, Kendrick AH, Nutt DJ. Behavioral and cardiovascular effects of 7.5% CO2 in human volunteers. Depress Anxiety. 2005;21(1):18-25.</citation>
    <PMID>15782425</PMID>
  </reference>
  <reference>
    <citation>Biancardi V, BÃ­cego KC, Almeida MC, Gargaglioni LH. Locus coeruleus noradrenergic neurons and CO2 drive to breathing. Pflugers Arch. 2008 Mar;455(6):1119-28. Epub 2007 Sep 13.</citation>
    <PMID>17851683</PMID>
  </reference>
  <reference>
    <citation>Pineda J, Aghajanian GK. Carbon dioxide regulates the tonic activity of locus coeruleus neurons by modulating a proton- and polyamine-sensitive inward rectifier potassium current. Neuroscience. 1997 Apr;77(3):723-43.</citation>
    <PMID>9070748</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 20, 2015</study_first_submitted>
  <study_first_submitted_qc>April 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2015</study_first_posted>
  <results_first_submitted>March 9, 2021</results_first_submitted>
  <results_first_submitted_qc>May 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2021</results_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT02410954/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>tDCS Electrode Configuration</title>
          <description>Three rounds of tDCS using NeuroConn Direct Current stimulator Multiple Channel -4, Rogue Resolutions treatment optimization where each round includes identifying a promising electrode configuration based on electric field modeling using a realistic head model and capitalizing on the experience with the prior round (for rounds 2 and 3) and testing that electrode placement by administering a series of electrical doses of tDCS with that tDCS electrode configuration (carrying out a dose titration) in a cohort of 10 healthy control subjects to see if we can find an electrical dose which is well-tolerated, safe, suppresses the AOT pupil response and is below recommended current density safety limits (the safety limit in terms of Amperage varies depending on the electrode configuration)&#xD;
NeuroConn Direct Current stimulator Multiple Channel -4: (tDCS) will be administered with a multichannel tDCS device that can be programmed so that the operator doesn't know the combination of electrodes being used for stimulation, and, thereby allow double-blinding. The active tDCS electrode configuration to be used will be determined with the 3 round iterative procedure described above; based on electric field modeling and personalized electrical dose titration to find the lowest dose that is well-tolerated and engages the target in terms of inhibiting the AOT pupillary response.</description>
        </group>
        <group group_id="P2">
          <title>Using tDCS to Reduce Acute Fear</title>
          <description>Administration of 7.5% CO2 to see if this elicits symptoms of Acute Fear and activates LC and whether tDCS safely inhibits the LC response to 7.5% CO2 compared with sham in a pilot cross-over trial (N=10). A 3-year double-blind, randomized, controlled trial where clinical symptoms of Acute Fear, the primary outcome are elicited with 7.5% CO2 in healthy volunteers is the final study component.&#xD;
NeuroConn Direct Current stimulator Multiple Channel -4: (tDCS) will be administered with a multichannel tDCS device that can be programmed so that the operator doesn't know the combination of electrodes being used for stimulation, and, thereby allow double-blinding. The active tDCS electrode configuration to be used will be determined with the 3 round iterative procedure described above; based on electric field modeling and personalized electrical dose titration to find the lowest dose that is well-tolerated and engages the target in terms of inhibiting the AOT pupillary response.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unable to collect usable data due to initial protocol issues</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Instrument malfunction generated unusable data</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The tDCS electrode configuration study was terminated prematurely due to technical problems and delay due to a move. The Using tDCS to reduce acute fear study was never started as a result.</population>
      <group_list>
        <group group_id="B1">
          <title>tDCS Electrode Configuration</title>
          <description>Three rounds of tDCS using NeuroConn Direct Current stimulator Multiple Channel -4, Rogue Resolutions treatment optimization where each round includes identifying a promising electrode configuration based on electric field modeling using a realistic head model and capitalizing on the experience with the prior round (for rounds 2 and 3) and testing that electrode placement by administering a series of electrical doses of tDCS with that tDCS electrode configuration (carrying out a dose titration) in a cohort of 10 healthy control subjects to see if we can find an electrical dose which is well-tolerated, safe, suppresses the AOT pupil response and is below recommended current density safety limits (the safety limit in terms of Amperage varies depending on the electrode configuration)&#xD;
NeuroConn Direct Current stimulator Multiple Channel -4: (tDCS) will be administered with a multichannel tDCS device that can be programmed so that the operator doesn't know the combination of electrodes being used for stimulation, and, thereby allow double-blinding. The active tDCS electrode configuration to be used will be determined with the 3 round iterative procedure described above; based on electric field modeling and personalized electrical dose titration to find the lowest dose that is well-tolerated and engages the target in terms of inhibiting the AOT pupillary response.</description>
        </group>
        <group group_id="B2">
          <title>Using tDCS to Reduce Acute Fear</title>
          <description>Administration of 7.5% CO2 to see if this elicits symptoms of Acute Fear and activates LC and whether tDCS safely inhibits the LC response to 7.5% CO2 compared with sham in a pilot cross-over trial (N=10). A 3-year double-blind, randomized, controlled trial where clinical symptoms of Acute Fear, the primary outcome are elicited with 7.5% CO2 in healthy volunteers is the final study component.&#xD;
NeuroConn Direct Current stimulator Multiple Channel -4: (tDCS) will be administered with a multichannel tDCS device that can be programmed so that the operator doesn't know the combination of electrodes being used for stimulation, and, thereby allow double-blinding. The active tDCS electrode configuration to be used will be determined with the 3 round iterative procedure described above; based on electric field modeling and personalized electrical dose titration to find the lowest dose that is well-tolerated and engages the target in terms of inhibiting the AOT pupillary response.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in VAS-A Rating</title>
        <description>Primary outcome will be the VAS-A &quot;fearful&quot; rating obtained at the end of tDCS/CO2 inhalation. AOT pupil response will be obtained every 10 minutes after the end of the tDCS/CO2 inhalation period to map the duration of persistent effects on LC.</description>
        <time_frame>Every 10 min (for approximately 20 minutes) at the end of tDCS/CO2 inhalation following one week post stimulation optimization.</time_frame>
        <population>No data are available to report as the instrument used malfunctioned and did not produce usable pupil measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>tDCS Electrode Configuration</title>
            <description>Three rounds of tDCS using NeuroConn Direct Current stimulator Multiple Channel -4, Rogue Resolutions treatment optimization where each round includes identifying a promising electrode configuration based on electric field modeling using a realistic head model and capitalizing on the experience with the prior round (for rounds 2 and 3) and testing that electrode placement by administering a series of electrical doses of tDCS with that tDCS electrode configuration (carrying out a dose titration) in a cohort of 10 healthy control subjects to see if we can find an electrical dose which is well-tolerated, safe, suppresses the AOT pupil response and is below recommended current density safety limits (the safety limit in terms of Amperage varies depending on the electrode configuration)&#xD;
NeuroConn Direct Current stimulator Multiple Channel -4: (tDCS) will be administered with a multichannel tDCS device that can be programmed so that the operator doesn't know the combination of electrodes being used for stimulation, and, thereby allow double-blinding. The active tDCS electrode configuration to be used will be determined with the 3 round iterative procedure described above; based on electric field modeling and personalized electrical dose titration to find the lowest dose that is well-tolerated and engages the target in terms of inhibiting the AOT pupillary response.</description>
          </group>
          <group group_id="O2">
            <title>Using tDCS to Reduce Acute Fear</title>
            <description>Administration of 7.5% CO2 to see if this elicits symptoms of Acute Fear and activates LC and whether tDCS safely inhibits the LC response to 7.5% CO2 compared with sham in a pilot cross-over trial (N=10). A 3-year double-blind, randomized, controlled trial where clinical symptoms of Acute Fear, the primary outcome are elicited with 7.5% CO2 in healthy volunteers is the final study component.&#xD;
NeuroConn Direct Current stimulator Multiple Channel -4: (tDCS) will be administered with a multichannel tDCS device that can be programmed so that the operator doesn't know the combination of electrodes being used for stimulation, and, thereby allow double-blinding. The active tDCS electrode configuration to be used will be determined with the 3 round iterative procedure described above; based on electric field modeling and personalized electrical dose titration to find the lowest dose that is well-tolerated and engages the target in terms of inhibiting the AOT pupillary response.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in VAS-A Rating</title>
          <description>Primary outcome will be the VAS-A &quot;fearful&quot; rating obtained at the end of tDCS/CO2 inhalation. AOT pupil response will be obtained every 10 minutes after the end of the tDCS/CO2 inhalation period to map the duration of persistent effects on LC.</description>
          <population>No data are available to report as the instrument used malfunctioned and did not produce usable pupil measurements.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <desc>No differences</desc>
      <group_list>
        <group group_id="E1">
          <title>tDCS Electrode Configuration</title>
          <description>Three rounds of tDCS using NeuroConn Direct Current stimulator Multiple Channel -4, Rogue Resolutions treatment optimization where each round includes identifying a promising electrode configuration based on electric field modeling using a realistic head model and capitalizing on the experience with the prior round (for rounds 2 and 3) and testing that electrode placement by administering a series of electrical doses of tDCS with that tDCS electrode configuration (carrying out a dose titration) in a cohort of 10 healthy control subjects to see if we can find an electrical dose which is well-tolerated, safe, suppresses the AOT pupil response and is below recommended current density safety limits (the safety limit in terms of Amperage varies depending on the electrode configuration)&#xD;
NeuroConn Direct Current stimulator Multiple Channel -4: (tDCS) will be administered with a multichannel tDCS device that can be programmed so that the operator doesn't know the combination of electrodes being used for stimulation, and, thereby allow double-blinding. The active tDCS electrode configuration to be used will be determined with the 3 round iterative procedure described above; based on electric field modeling and personalized electrical dose titration to find the lowest dose that is well-tolerated and engages the target in terms of inhibiting the AOT pupillary response.</description>
        </group>
        <group group_id="E2">
          <title>Using tDCS to Reduce Acute Fear</title>
          <description>Administration of 7.5% CO2 to see if this elicits symptoms of Acute Fear and activates LC and whether tDCS safely inhibits the LC response to 7.5% CO2 compared with sham in a pilot cross-over trial (N=10). A 3-year double-blind, randomized, controlled trial where clinical symptoms of Acute Fear, the primary outcome are elicited with 7.5% CO2 in healthy volunteers is the final study component.&#xD;
NeuroConn Direct Current stimulator Multiple Channel -4: (tDCS) will be administered with a multichannel tDCS device that can be programmed so that the operator doesn't know the combination of electrodes being used for stimulation, and, thereby allow double-blinding. The active tDCS electrode configuration to be used will be determined with the 3 round iterative procedure described above; based on electric field modeling and personalized electrical dose titration to find the lowest dose that is well-tolerated and engages the target in terms of inhibiting the AOT pupillary response.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study terminated prematurely without generating any outcome data due to delays due to the study being moved from one institution to another and due to technical problems with the pupil measurements that required a long period of trouble-shooting/problem-solving and ultimately the replacement of the pupillometry device.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Andrew Krystal, MD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>(415) 476-7702</phone>
      <email>andrew.krystal@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

